AN2 Therapeutics
Update in progressANTX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
AN2 Therapeutics, Inc. is a Menlo Park, California-based biopharmaceutical company developing boron-based small molecules. Its lead candidate, epetraborole, is a once-daily oral therapy in Phase 3 for non-tuberculous mycobacterial lung disease and is being explored for acute melioidosis. It also works on AN2-502998 (AN15368) in preclinical stages for chronic Chagas disease, plus other oncology and infectious disease programs. It licenses epetraborole from Anacor, and collaborates with Brii Biosciences in Greater China and with GSK on TB research.
Company score
- Sentiment
- 0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!